Arthrotec is a combination drug indicated for osteoarthritis (OA) or rheumatoid arthritis (RA) in patients at high risk for developing NSAID-induced gastric or duodenal ulcers. Diclofenac Sodium, an NSAID, exerts greater selectivity for COX-2 than COX-1 and is an effective analgesic, inflammatory agent. Misoprostol, a prostaglandin E1 analogue, is used in combination with diclofenac therapy to help protect against gastrointestinal ulceration.
Watson expects to launch this product in the fourth quarter of 2012.
For more information call (800) 272-5525 or visit www.watson.com.